Diseases-and-Conditions

Does Pfizer Offer Good Value?

Over the past 12 months, Pfizer has underperformed the S&P 500 by a wide margin. The company is just 4.6% ahead of the benchmark over...

Is Idera's Sell-Off Premature?

Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a...

Why Insmed Incorporated Shares Sank

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in...